A vs ADSK Stock Comparison

Scores Breakdown

Metric	A	ADSK
📈 Growth	18/30	28/30
💰 Profitability	16/20	18/20
🏦 Financial Health	7/20	12/20
💵 Valuation	9/20	12/20
⚠️ Risk (lower is better)	7/10	5/10
Overall Score	53/100	75/100

Side-by-Side Summaries

A Analysis	ADSK Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from roughly $1.50B to $1.93B, and Net Income grew from about $275M to $491M, delivering a clear top‑ and bottom‑line uptrend. The sequence shows steady sequential gains with only modest quarterly volatility, translating to ~29% revenue growth and ~78% net income growth across the period. 💰 Margins & Cash Flow Gross margins run in the mid‑to‑high 80s percent range, with Gross Profit margin staying strong relative to Revenues. Operating leverage appears favorable as operating income remains healthy while R&D and other investments persist. Cash flow from operations is consistently positive, often in the hundreds of millions (e.g., ~$460–$564M), with occasional financing outflows; investing cash flow is modest and generally supportive of ongoing growth. 🛡️ Balance Sheet & Liquidity Total assets hover around $9.5–11B and long‑term debt sits near $2.3–2.5B, yielding a balance sheet with solid equity (around $2.5–3.1B). Current liabilities and assets are balanced enough to sustain operations, providing resilience through moderate liquidity headroom. ⚠️ Key Drivers & Risks Drivers: AI-enabled design features and expanding cloud adoption. Risks: Valuation sensitivity to multiples and near‑term liquidity headroom pressures from financing activities.

A Analysis

ADSK Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from roughly $1.50B to $1.93B, and Net Income grew from about $275M to $491M, delivering a clear top‑ and bottom‑line uptrend. The sequence shows steady sequential gains with only modest quarterly volatility, translating to ~29% revenue growth and ~78% net income growth across the period.

💰 Margins & Cash Flow

Gross margins run in the mid‑to‑high 80s percent range, with Gross Profit margin staying strong relative to Revenues. Operating leverage appears favorable as operating income remains healthy while R&D and other investments persist. Cash flow from operations is consistently positive, often in the hundreds of millions (e.g., ~$460–$564M), with occasional financing outflows; investing cash flow is modest and generally supportive of ongoing growth.

🛡️ Balance Sheet & Liquidity

Total assets hover around $9.5–11B and long‑term debt sits near $2.3–2.5B, yielding a balance sheet with solid equity (around $2.5–3.1B). Current liabilities and assets are balanced enough to sustain operations, providing resilience through moderate liquidity headroom.

⚠️ Key Drivers & Risks

Drivers: AI-enabled design features and expanding cloud adoption.
Risks: Valuation sensitivity to multiples and near‑term liquidity headroom pressures from financing activities.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"